MPs examine barriers to accessing innovative cancer treatments
MPs will examine action needed to speed up the adoption of innovations in cancer treatment if the UK is to retain its position as a global leader on the science. Previous evidence to the Future cancer inquiry has heard that the UK is viewed as an increasingly less favourable place to conduct clinical research or trials, with a ‘pedestrian’ approach to approving use and getting innovative treatments to patients.
Facing questions, two panels combining expertise in innovation, biological therapy engineering, and cancer research with representatives from the medicines’ agency NICE and regulator, the MHRA. Areas likely to be covered include: improving access to innovative treatments; barriers to translating innovations to clinical settings; the UK’s international standing as a centre for commercial research and development.
The Committee is examining innovations with the greatest potential to transform cancer diagnosis and treatment for patients in the short, medium and long term, and how they can best be transitioned into frontline clinical settings.